Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form

被引:3
|
作者
Cook, CS [1 ]
Zhang, LM [1 ]
机构
[1] Pharmacia Corp, Metab & Safety Evaluat, Skokie, IL 60077 USA
关键词
eplerenone; dog; interconversion pharmacokinetics; lactone ring;
D O I
10.1002/jps.10124
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The interconversion pharmacokinetics of eplerenone and its lactone-ring open form, SC-70303, were examined in dogs using a stable isotope method. [(CD3)-C-13]EP and SC-70303 were coadministered orally (10 mg/kg) and intravenously (5 mg/kg) as aqueous solutions under fasted conditions. After I.V. administration of [(CD3)-C-13]EP, the mean AUC of [(CD3)-C-13]EP was 16.0 h (.) mug/mL, while the C-max, T-max, and AUC for [(CD3)-C-13]SC-70303 acid were 0.744 mug/mL, 0.5 h, and 3.49 h (.) mug/mL, respectively. After I.V. administration of SC-70303, the AUC for SC-70303 acid was 6.36 h (.) mug/mL, while the C-max, T-max, and AUC for EP were 2.26 mug/mL, 0.5 h, and 9.48 h (.) mug/mL, respectively. After oral administration of [(CD3)-C-13]EP, the C-max, T-max, and AUC for [(CD3)-C-13]EP were 6.01 mug/mL, 0.5 h, and 27.7 h (.) mug/mL, respectively, and the corresponding values for [(CD3)-C-13]SC-70303 acid were 0.972 mug/mL, 0.75 h, and 5.52 h (.) mug/mL, respectively. After oral administration of SC-70303, the Cmax, Tmax, and AUC for EP were 1.38 mug/mL, 0.83 h, and 9.29 h (.) mug/mL, respectively, and the corresponding values for SC-70303 acid were 0.330 mug/mL, 0.67 h, and 2.19 h (.) mug/mL, respectively. The systemic availability was 90% for [(CD3)-C-13]EP and 17.5% for SC-70303 acid. EP and SC-70303 acid were rapidly interconvertible in the dog. The percentage of dose converted to [(CD3)-C-13]SC-70303 acid following I.V. administration of [(CD3)-C-13]EP was 55.0%, while the percentage of dose converted to EP following I.V. administration of SC-70303 was 60.2%. (C) 2002 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 91:1383-1389, 2002.
引用
收藏
页码:1383 / 1389
页数:7
相关论文
共 39 条
  • [21] Effect of eplerenone, a selective aldosterone blocker, on adiposal renin-angiotensin-aldosterone system in saltsensitive hypertensive rats
    Zhu, Aoshuang
    Takeda, Yoshiyu
    Usukura, Mikiya
    Yoneda, Takashi
    Takata, Hiroyuki
    Karashima, Shigehiro
    Sakai, Satoko
    Yamagishi, Masakazu
    JOURNAL OF HYPERTENSION, 2006, 24 : 312 - 312
  • [22] Effect of Eplerenone, a Selective Aldosterone Blocker, on the Development of Diabetic Nephropathy in Type 2 Diabetic Rats
    Ahn, Jae Hee
    Hong, Ho Cheol
    Cho, Myong Jin
    Kim, Yoon Jung
    Choi, Hae Yoon
    Eun, Chai Ryoung
    Yang, Sae Jeong
    Yoo, Hye Jin
    Kim, Hee Young
    Seo, Ji A.
    Kim, Sin Gon
    Choi, Kyung Mook
    Baik, Sei Hyun
    Choi, Dong Seop
    Kim, Nan Hee
    DIABETES & METABOLISM JOURNAL, 2012, 36 (02) : 128 - 135
  • [23] Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension
    Burgess, ED
    Lacoucière, Y
    Ruilope-Urioste, LM
    Oparil, S
    Kleiman, JH
    Krause, S
    Roniker, B
    Maurath, C
    CLINICAL THERAPEUTICS, 2003, 25 (09) : 2388 - 2404
  • [24] Assessment of the new selective aldosterone blocker eplerenone on 24-hour ambulatory blood pressure
    White, WB
    Oigman, W
    Mion, D
    Lewin, A
    Roniker, B
    Jordan, R
    Kleiman, J
    Nusbaum, I
    JOURNAL OF HYPERTENSION, 2002, 20 : S169 - S169
  • [25] Effects of eplerenone, a selective aldosterone blocker, on blood pressure and organ damage in adrenalectomized hypertensive rats
    Takeda, Yoshiyu
    Zhu, Aoshuang
    Yoneda, Takashi
    Usukura, Mikiya
    Takata, Hiroyuki
    Karashima, Shigehiro
    Sakai, Satoko
    Yamagishi, Masakazu
    JOURNAL OF HYPERTENSION, 2006, 24 : 85 - 85
  • [26] Treatment with eplerenone, a selective aldosterone blocker, improved ventricular remodelling and function post-myocardial infarction
    Le, J
    Rocha, R
    Rudolph, A
    Dawood, F
    Wen, W
    Rouleau, JL
    Liu, P
    EUROPEAN HEART JOURNAL, 2003, 24 : 528 - 528
  • [27] Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy
    Wahed, MII
    Watanabe, K
    Ma, ML
    Yamaguchi, K
    Takahashi, T
    Tachikawa, H
    Kodama, M
    Aizawa, Y
    PHARMACOLOGY, 2005, 73 (02) : 81 - 88
  • [28] Selective aldosterone blocker, eplerenone increases cardiac angiotensin 2 expression in salt-sensitive hypertension
    Takeda, Y
    Zhu, A
    Yoneda, T
    Usukura, M
    Takata, H
    Oda, N
    Yamamoto, Y
    JOURNAL OF HYPERTENSION, 2005, 23 : S49 - S50
  • [29] Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction
    Masson, S
    Staszewsky, L
    Annoni, M
    Carlo, E
    Arosio, B
    Bai, A
    Calabresi, C
    Martinoli, E
    Salio, M
    Fiordaliso, F
    Scanziani, E
    Rudolph, AE
    Latini, R
    JOURNAL OF CARDIAC FAILURE, 2004, 10 (05) : 433 - 441
  • [30] Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension
    White, WB
    Carr, AA
    Krause, S
    Jordan, R
    Roniker, B
    Oigman, W
    AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (01): : 38 - 42